Xtandi is a drug used to treat prostate cancer. It is a type of androgen receptor inhibitor, which works by blocking the action of male hormones that can cause the growth of prostate cancer cells. Xtandi is used to treat metastatic castration-resistant prostate cancer (mCRPC) in men who have already received medical or surgical treatments to lower testosterone levels. It is also used to treat non-metastatic castration-resistant prostate cancer (nmCRPC) in men who have not received prior treatments to lower testosterone levels. Xtandi is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2012. It is currently the only FDA-approved androgen receptor inhibitor for the treatment of prostate cancer. Xtandi is marketed by Astellas Pharma, a Japanese pharmaceutical company, and is distributed in the US by Medivation, a subsidiary of Pfizer. Other companies involved in the market include Johnson & Johnson, Sanofi, and Bayer. Show Less Read more
ASK A QUESTION
We request your telephone number so we can contact you in the event we have difficulty reaching you via email. We aim to respond to all questions on the same business day.
